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Treatment is effective in reducing heroin use and clinical and social problems among
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drug treatment centers and 10,454 heroin users. Clinical and personal information were
collected at intake through a structured interview. Treatments were recorded using a
standardized form. Survival analysis and Cox Proportional Hazard model were used to
evaluate treatment retention. Five thousand four hundred and fifty-seven patients who
started a treatment in the 18 months of the study were included in the analysis: 43.2%
received methadone maintenance therapy (MMT), 10.5% therapeutic community, and
46.3% abstinence-oriented therapy (AOT). The likelihood of remaining in treatment was
0.5 at 179 days. The median daily dose of methadone was 37 mg. Psychotherapy was
provided in 7.6% of patients receiving methadone and 4.9% of those in therapeutic com-
munity. Type of therapy was the strongest predictor of retention, with AOT showing the
lowest retention. In MMT patients, retention improved according to dose. Living alone,
psychiatric comorbidity and cocaine use increased the risk of dropout. Psychotherapy
associated halved the risk of dropout.
Keywords heroin addiction; treatment retention; methadone maintenance; methadone
dose; therapeutic community; psychotherapy
Introduction
Treatment of heroin addiction is effective in reducing heroin use and related clinical and
social problems (Amato, Davoli, Ferri, Gowing, and Perucci, 2004; Marsch, 1998; Mattick,
Breen, Kimber, and Davoli, 2009; NIDA, 2000; Ward, Hall, and Mattick, 1999). Results
from large-scale observational studies, such as the Drug Abuse Treatment Outcome Study
(DATOS) (Simpson, Joe, and Brown, 1997b) and the National Treatment Outcome Research
Study (NTORS) (Gossop, Marsden, Stewart, and Treacy, 2001), suggest that the extent of the
reduction is associated with the duration of treatment. In this light, retention in treatment has
been considered as an appropriate and measurable proxy of the effectiveness of treatment
(Zhang, Friedmann, and Gerstein, 2003).
In Italy, treatment of heroin addiction is provided by the National Health Service (NHS)
through a network of drug treatment centers (SerT). As of 2005, there were 535 treatment
centers distributed throughout the country, and 180,117 patients were treated (Ministero
della Solidarieta` Sociale, 2006) (corresponding to 0.31% of Italy’s population). The centers
provide a wide range of individually tailored pharmacological and psychosocial treatments
at no cost to the individual, mainly on an outpatient basis. When residential treatment
is prescribed, the individual is referred to a therapeutic community. These communities
are generally run by nongovernmental organizations (NGO), yet the cost of residential
treatment is covered by the NHS, whose personnel supervise treatment.
In 1997, the Italian Ministry of Health decided to evaluate the effectiveness of the
treatments provided by the drug treatment centers. Following the example of DATOS and
NTORS, a large-scale follow-up study was launched. The study, known as “VEdeTTE”
(an Italian acronym meaning “the evaluation of the effectiveness of treatment for heroin
dependence”) focuses on mortality (Davoli et al., 2007) and retention in treatment in relation
to the treatment provided. In the present work, we describe the effectiveness of treatments
in terms of retention.
Methods
A pragmatic sample of 115 treatment centers were selected in 13 regional health offices as
representative of the whole of regional treatment centers and participated in the cohort. To
evaluate the representativeness of the cohort, the enrolled patients were compared to the
population under treatment for opiate addiction in Italy in 1999, and no major differences
Su
bs
t U
se
 M
isu
se
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 S
tu
di
 D
i T
or
in
o 
on
 1
2/
12
/1
3
Fo
r p
er
so
na
l u
se
 o
nl
y.
2078 Salamina et al.
were observed, apart from a lower proportion of new cases (11.5% in the cohort vs. 21.1%
in the opiate addicted population, p < .01) (Bargagli et al., 2006).
During the study period (lasting 18 months, from September 1998 to March 2001),
10,454 heroin addicts provided informed consent and were enrolled. Upon enrollment,
clinical history and personal information were collected by center personnel through a
structured interview.
Information about treatment was collected for 18 months from the start of the study.
Using a standardized form, the personnel of the centers collected detailed information
on each episode of the following treatments: methadone maintenance; detoxification with
tapering doses of methadone; detoxification with nonopiate drugs (in- and outpatient based);
maintenance with naltrexone; therapy with psychotropic drugs; psychotherapy; counseling;
job guidance; social advice; and residential and semiresidential treatment (semiresidential
patients do not spend the night at the facility).1 All treatments were provided on an outpatient
basis by the centers’ personnel, except for residential and semiresidential treatments and,
in certain cases, inpatient detoxification. The following information was collected: type
of treatment; mean dose (for methadone treatments), starting and closing date. For further
details about the study design and population, see Bargagli et al. (2006).
In order to study the retention in treatment and its determinants, the analysis was
limited to the first therapy started during the study period. This selection limited the study
population to 5,457 subjects since the 4,816 patients who have an ongoing therapy at the
beginning of the study and that did not start a second therapy in the 18 months of the study
were not included in the analysis. Patients’ therapies ongoing at the beginning of the study
were excluded from the analysis because they referred to a selected group of patients who
had “survived” to the treatment within the whole group of patients who started the treatment
before the beginning of the study. The inclusion of these therapies would have caused an
underestimation of the risk of dropout.
For the purpose of the analysis the included patients were classified according to the
undergone treatment as follows:
1. Therapeutic community (TC), whatever additional treatment they received;
2. Patients not in TC, undergoing a methadone maintenance therapy (MMT), whatever
additional treatment they received;
3. Patients not in a TC and not undergoing a MMT, receiving solely treatments aimed
at abstinence (i.e., naltrexone maintenance, semiresidential treatments, detoxifica-
tions, psychotherapy, counseling, social advice, job guidance, psychotropic drug
treatments).
This set of treatments was identified as a specific strategy of treatment called
“abstinence-oriented therapy” (AOT).
When abstinence-oriented treatments were offered closely before a therapeutic commu-
nity or a methadone maintenance (n = 1,260/2,931), they were considered as a preliminary
1Treatment can be briefly and usefully defined as a planned, goal directed, temporally structured
change process, of necessary quality, appropriateness and conditions (endogenous and exogenous;
micro to macro levels)), which is bounded (culture, place, time, etc.) and can be categorized into
professional-based, tradition-based, mutual-help-based (AA,NA, etc.), and self-help (“natural recov-
ery”) models. There are no unique models or techniques used with substance users—of whatever
types and heterogeneities—which are not also used with nonsubstance users. In the West, with the
relatively new ideology of “harm reduction” and the even newer Quality of Life (QOL) treatment-
driven model there are now a new set of goals in addition to those derived from/associated with the
older tradition of abstinence driven models. Editor’s note
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phase of the following MMT or TC and not as a therapy itself. The preliminary phase was
analyzed as a covariate of the therapy, and it was excluded by the calculation of the duration
of therapy.
For the purposes of the survival analysis, any abandoning of treatment longer than 21
days, whatever the reason, was considered a failure. Therapies still ongoing at the end of
the study period (18 months), or those stopped within 21 days from the end of the follow-
up, were treated as right-censored. Kaplan–Meier product-limit estimator was calculated
overall and for each group stratification, according to relevant patients’ characteristics;
log-rank test was used to assess statistical significance. A Cox Proportional Hazard model
was built for the maximum likelihood estimation of the risk of dropout (Kleinbaum, 1996).
Models were fitted following a backward procedure from a saturated model, including the
most relevant information collected in the interview, particularly those suspected to play
as confounders. Gender was always retained in the model independently by significance.
Likelihood-ratio test was used to assess the fitness of models. Because of the difference
in the distribution of type of patient between the cohort and the total of patients treated in
Italy and because type of patient was an effect modifier in the graphical analysis, the model
was stratified for new and reentry patients.
Results
A total of 5,457 heroin users were included in the analysis: 1,216 (22.3%) were seen for the
first time by the treatment center (new patients) and 4,241 (77.7%) had already been seen by
the center in the past (retreated patients). In Table 1 are described the main characteristics
of the study population.
Methadone maintenance was the first therapy for 43.2% of cases (n = 2,356), both in
new and retreated patients (Table 2). The median dose of methadone was 37 mg; 15.1% of
patients receiving 60 mg or more; 75.9% between 20 and 59 mg; and 9.0% less than 20
mg (data not shown). Before starting a MMT, 41.4% of patients underwent a preliminary
period of treatment (Table 3), a quarter of them (27.0% new patients vs. 25.1% retreated
patients; p = .377—data not shown) including tapering methadone.
Therapeutic community was the first therapy for 10.5% of cases (n = 575) (Table 2):
11.6% and 6.7% (p < .001) for retreated and new patients, respectively. Half of patients
started the therapeutic community with a preliminary treatment (Table 3), 20% of them
including a tapering methadone and 30% other abstinence-oriented treatments (data not
shown).
Preliminary phase was observed in similar proportion in new and retreated patients
(53.7% vs. 48.9%; p = .423—data not shown) with a median duration of approximately
one month and half for both MMT and TC (Table 3).
During MMT and TC, patients received various supporting treatments, as counseling,
social advice, and job guidance. Psychotherapy was provided to 7.6% of patients in MMT
and to 4.9% of those in TC. Tapering methadone was rarely carried out in TC (0.9%) and
limited to the very beginning of the treatment (Table 3).
AOT was the most frequent first therapy (46.3%; n = 2,526), in both new (49.7%) and
retreated patients (45.3%). These patients received a great variety of pharmacological and
nonpharmacological treatments: naltrexone (13.9%); single (37.5%) or repeated methadone
detoxifications (14.3%); psychotherapy (12.7%); counseling, social support, or nonopiate
detoxifications (55.0%) (data not shown). If patients receiving abstinence-oriented inter-
ventions as preliminary treatment were also taken into account (23.1%) (Table 3), the
overall proportion of patients first treated with this type of treatments increased to 69.4%.
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Table 2
Therapies observed during the 18-month period of the study among the VEdeTTE
patients selected for the analysis of retention
New patients Retreated patients All
First therapy n % n % n %
Methadone
maintenance
530 43.6 1,826 43.1 2,356 43.2
Therapeutic
community
82 6.7 493 11.6 575 10.5
Abstinence-oriented
therapies
604 49.7 1,922 45.3 2,526 46.3
Total 1,216 100 4,241 100 5,457 100
Overall, 44.1% patients were still under treatment at the end of the study period (54.4%
of MMT, 47.8% of TC, and 33.7% of AOT). Within the study period, overall 33.0% of
patients restarted a second therapy (28.1% of MMT, 39.0% of TC, and 36.1% of AOT),
while 23% stopped the therapy and did not come back (17.5% of MMT, 13.2% of TC, and
30.2% of AOT) (Table 3).
Retention in MMT, TC, and AOT
The overall likelihood of remaining in treatment was 0.5 at 179 days, i.e., 50% of patients
were still under treatment after 179 days of therapy. The most significant predictor of re-
tention in treatment was type of therapy, with some differences between new and retreated
patients (Figure 1). Regardless to the type of therapy, the association with psychother-
apy improved treatment retention: the median likelihood of retention was 315 days with
psychotherapy vs. 167 days without (p = .001).
Among new patients in MMT, 50% were still under treatment after 307 days (Figure 1),
as well as those in TC; however the difference among the two therapies was not statistically
significant (p = .087). Among retreated patients, the median likelihood of retention were
300 days for patients under MMT and 169 days for patients in TC (p < .001). In this group,
days
0 30 90 180 365 540
0.00
0.25
0.50
0.75
1.00
abstinence oriented
methadone maintenance
therapeutic community
re-treated patients
days
0 30 90 180 365 540
0.00
0.25
0.50
0.75
1.00
abstinence oriented
methadone maintenance
therapeutic community
new patients
Figure 1. Kaplan–Meyer survival estimate of retention in treatment, by type of therapy and type of
patient. n = 5,457.
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MMT had a better retention among those who underwent a preliminary phase compared
to those who did not: the median likelihood of retention corresponded to 340 days and
274 days, respectively (p = .004). Among patients undergoing MMT, retention improved
according to dose.
In both groups of patients, AOT showed the lowest retention (p < .001, in comparison
with the other two therapies): after 107 and 101 days of treatment, 50% of new and retreated
patients, respectively, were still under treatment.
Results of Cox’s Multivariate Analysis
In Cox’s multivariate analysis (Table 4), few sociodemographic and clinical characteristics
significantly confounded the relationship between type of therapy and retention. Since
therapies had different patterns of prediction between new and retreated patients, two models
were carried out. Type of therapy was confirmed as the strongest predictor of retention.
Among new patients, those who were treated in TC showed nonsignificant differences
compared to those who underwent MMT at 60 mg or more daily. Compared to the latter,
all other therapies showed significant increases of risk of dropout. Living alone, psychiatric
comorbidity, and cocaine use significantly increased the risk of stopping therapy.
Among retreated patients, those who underwent MMT at 60 mg or more daily showed
the best retention. Among MMT patients, the lower the dose, the higher the risk of stopping
therapy. Compared to MMT at 60 mg or more, the risk of stopping therapy was 1.85 (95%CI:
1.47–2.34) times higher among patients treated in TC and 3.27 (95%CI: 2.65–4.03) among
those who received AOT. The risk of stopping therapy was associated to young age, and
a slight additional risk of stopping was seen among patients living alone (1.18; 95%CI:
1.05–1.33).
In both groups of patients, regardless to the type of therapy, if no psychotherapy
or no psychosocial treatment was associated to therapy, the risk of stopping increased
of approximately two times. The absence of a preliminary phase before MMT increased
the risk of stopping of 29% (1.29; 95%CI: 1.14–1.46; the risk was estimated in a model
restricted to patients in MMT—data not shown).
Discussion
The analysis of the VEdeTTE study, a large Italian cohort of heroin addicts, showed the
greatest retention for MMT when administered at a daily dose of 60 mg or more. Patient’s
history determines retention differences: among patients undergoing their first treatment,
retention was similar when receiving TC and MMT, except for those receiving very low
doses of methadone. Among retreated patients, who return for a new treatment after a
relapse, TC as well as AOT, and AOT for all patients, show a higher risk of dropout and
should be, therefore, considered with caution.
These findings were fairly expected and are consistent with the results of cohorts
(Gossop et al., 2001; Simpson et al., 1997a), randomized controlled trials (Johnson, Jaffe,
and Fudala, 1992; Johnson et al., 2000; Strain, Bigelow, Liebson, and Stitzer, 1999), and
systematic reviews (Faggiano, Vigna-Taglianti, Versino, and Lemma, 2003; Mattick et al.,
2009). They are also highly consistent with the results of the analysis on mortality in the
same cohort: MMT showed the lowest mortality both during treatment and after the end of
the treatment (Davoli et al., 2007).
This evidence raises the concern on the treatments offered by the Italian NHS drug
treatment centers: 46.3% of patients received AOT as first treatment, most consisting of
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repeated detoxification attempts, supported by counseling and social advice. Centers often
combine these treatments as a first stage of any therapy, presumably to establish a better
relationship with patients and to increase motivation and acceptance of therapy itself.
However, these treatments do not allow to maintain long-term abstinence (Amato, Davoli,
Minozzi, Ali, and Ferri, 2005; Caplehorn, McNeil, and Kleinbaum, 1993; D’Ippoliti, Davoli,
Perucci, Pasqualini, and Bargagli, 1998) and do not ensure good compliance to treatment; in
the VEdeTTE study subjects receiving AOT did not continue these therapies for more than
100 days and showed the worst retention. The limited retention of AOT could be inherent
to treatment, since it is aimed at abstinence, and consequently is a definitive recovery
associated with treatment,2 but, considering the short term of the VEdeTTE follow-up, it
is properly a failure. Given the defined chronic nature of addiction3 (McLellan, O’Brien,
Lewis, and Kleber, 2000), a medium to long-term treatment should be always set up after
detoxification to prevent relapse.
The proportion of patients under MMT is 43.2% and it can be considered to be quite
low if considering the higher effectiveness of MMT reported by randomized-controlled
trials (Strain, Stitzer, Leibson, and Bigelow, 1993; Vanichseni et al., 1991; Yancovitz
et al., 1991). Furthermore MMT was on average prescribed at ineffective doses: only 15%
of patients receive at least a daily dose of 60 mg, as recommended by scientific literature
(Faggiano et al., 2003), whereas about 10% of them receive less than 20 mg of methadone
daily, and their risk of discontinuing therapy is three times higher among new patients and
two times higher among retreated patients, compared to patients receiving 60 mg or more.
The great majority of patients underwent MMT at doses between 20 and 59 mg daily, and
they showed a risk of discontinuing therapy about 40% higher than patients receiving 60
mg or more. These data reflect the effect of a more than 10 years-long pressure against
MMT driven by some Italian political parties and by the religious contexts, pressure that
seems to be lasted in the last years of 1990s.
Some components of treatments seem to increase retention. Psychosocial treatments,
when added to whatever therapy, showed a higher than 80% significant increase in re-
tention. Randomized-controlled trials showed an effect of psychosocial components on
MMT, especially on heroin use (Amato, Minozzi, Davoli, Vecchi, Ferri, and Mayet, 2008;
McLellan, Arndt, Metzger, Woody, and O’ Brien, 1993), but not on retention (Amato et al.,
2008). It is likely that when these combined interventions are offered to clients together with
an under-dosed methadone maintenance, they may improve the effectiveness in preventing
relapse, as already shown in alcohol-dependence research (Stout, Rubin, Zwick, Zywiak,
and Bellino, 1999). Psychotherapy in particular increased retention rates even more than
other psychosocial treatments, regardless the type of therapy associated. It is possible that
psychotherapy may have been prescribed to selected patients with low severity and/or
higher level of motivation, who had an increased likelihood of experiencing high retention
rates. Although this result was adjusted for main confounders, including patients’ severity,
it is possible that some degree of residual confounding still remained. Nevertheless, given
the strength of the estimated hazard ratio (HR = 2.03 and HR = 2.01 in new and retreated
2The reader is referred to Hills’s criteria for causation which were developed in order to help
assist researchers and clinicians determine if risk factors were causes of a particular disease or
outcomes or merely associated, (Hill, 1965). The environment and disease: associations or causation?
Proceedings of the Royal Society of Medicine 58: 295–300.). Editor’s note.
3The reader is referred to the “natural recovery” literature which documents cessation of use
of a range of psychoactive drugs without professional-based, tradition-based, or mutual-help-based
(AA,,NA,.). Editor’s note.
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patients respectively), residual confounding do not appear to completely explain the result
obtained.
Retention in MMT seemed to be enhanced by adding to MMT and TC a preliminary
phase, consisting in a set of psychosocial treatments together with some attempts of detox-
ification. Although this result confirms the crucial role of patient–clinician relationship,
particularly in first contacts in order to motivate patient to undertake a long therapy, it could
be nation-specific effect, to motivate patients unwilling to enter in a long-term methadone
therapy, conditioned by the ideological pressure against MMT.
Study’s Limitations
The results presented here came from an observational study with an 18-month individual
follow-up, and this is the origin of some limitations: for example, treatments were consid-
ered concluded when the interruption was longer than three weeks: therefore, any treatment
stopped during the study period was considered as a failure, though some of those therapies
may have concluded successfully, according to clinician. The threshold of three weeks
was chosen a priori for clinical considerations. Moreover, in order to limit the effect of
selection bias we excluded ongoing therapies at the start of the study, and treatments were
regrouped in three simplified patterns of therapy to synthesize the information collected.
These choices limit the external validity of the study, together with any comparison of
VEdeTTE treatment durations with those observed in other similar studies. Besides, even
if the regression models have been adjusted for various potential confounders, VEdeTTE
study remains an observational study with the typical limitations in the interpretation of re-
sults due to residual uncontroled biases. Nevertheless, under the assumption that addiction
is a chronic condition (Leshner, 1997; McLellan, 2002) requiring treatments longer than
two years (McLellan et al., 2000), retention can be considered as an appropriate indicator
of the effectiveness of treatment started during the 18 months of the study.
In spite of all possible limitations, studies like VEdeTTE have a basic importance for
the evaluation of the effectiveness of therapies: in fact they provide the unique possibility
to study the occurrence of outcomes in the “real world,” where patients are not randomized,
treatments are not optimal, resources are limited. As reported by McLellan, treatment is
expected to produce symptoms reduction only as long as the patient is actively involved
in that treatment (McLellan, 2002). Results from VEdeTTE study suggest that appropriate
choice of treatment and dose, correct evaluation of patient’s treatment history, and associ-
ation with psychosocial treatments can have a relevant impact in patient outcomes even in
daily practice.
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R ´ESUM ´E
Le traitement est efficace pour re´duire l’usage de l’he´roı¨ne, ainsi que les proble`mes
me´dicaux ou sociaux des usagers d’he´roı¨ne. L’efficacite´ du traitement est lie´e a` sa dure´e.
Vedette est une e´tude italienne longitudinale finance´e par le ministe`re de la Sante´ qui a pour
objectif d’e´valuer les traitements dispense´s par les services de sante´ nationaux. L’e´tude
a concerne´ 115 centres de traitement de la toxicomanie et 10454 usagers d’he´roı¨ne. Des
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donne´es personnelles et cliniques ont e´te´ recueillies au moment de la mise sous traite-
ment au cours d’un entretien structure´. Les donne´es concernant les traitements ont e´te´
recueillies a` l’aide d’un formulaire standardise´. Une analyse de survie avec mode`le de
Cox a e´te´ effectue´e pour e´valuer la re´tention en traitement. Au total, 5457 patients qui ont
commence´ un traitement pendant la pe´riode d’e´tude ont e´te´ inclus dans l’analyse: 43,2%
recevaient un traitement de substitution par me´thadone, 46,3% des the´rapies oriente´es vers
l’abstinence et 10,5% e´taient en communaute´s the´rapeutiques. La dose journalie`re me´diane
de me´thadone e´tait de 37 mg. 7,6% des patients sous me´thadone et 4,9% de ceux en com-
munaute´s the´rapeutiques be´ne´ficiaient d’une psychothe´rapie. La probabilite´ de re´tention en
traitement e´tait de 50% a` 179 jours. Le type de the´rapie e´tait le facteur pre´dictif de re´tention
en traitement le plus fort, les the´rapies de sevrage e´tant associe´es a` la probabilite´ la plus
faible. Chez les patients recevant un traitement de substitution par me´thadone, la probabilite´
de re´tention en traitement augmentait avec la dose de me´thadone. Vivre seul, une comor-
bidite´ psychiatrique et une consommation de cocaı¨ne augmentait le risque d’abandon du
traitement. L’association d’une psychothe´rapie au traitement re´duisait de moitie´ le risque
d’abandon du traitement.
RESUMEN
El tratamiento para adiccio´n a opia´ceos es efectivo, reduce el uso de la heroı´na y las
consecuencias clı´nicas y sociales de los adictos. La efectividad del tratamiento depende
de la duracio´n del mismo. “VEdeTTE” es un estudio de cohorte italiano financiado por el
Ministerio de la Salud con el objetivo de evaluar la eficacia de los tratamientos procurados
por el Servicio Pu´blico de Salud para la to´xico dependencia. Participaron 115 Centros
y 10,454 adictos a la heroı´na. La informacio´n clı´nica, personal y socio-demogra´fica de
los pacientes fue recogida a trave´s de una entrevista estructurada. La informacio´n sobre
los tratamientos recibidos fueron relevados mediante instrumentos estandarizados. Para
evaluar la retencio´n al tratamiento se utilizaron ana´lisis de sobrevida y el modelo de Cox.
Fueron incluidos en el ana´lisis 5,457 pacientes que iniciaron el tratamiento durante el
perı´odo de 18 meses: el 43.2% recibio´ un tratamiento de mantenimiento con metadona, el
10.5% un tratamiento de comunidad terape´utica residencial y el 46.3 una terapia orientada
a la abstinencia. La probabilidad de restar en tratamiento fue del 0.5 despue´s de 179
dı´as de tratamiento. La dosis mediana de metadona diaria fue de 37 mg. El 7.6% de
los pacientes que recibieron metadona y el 4.9% de aquellos enviados en comunidad
terape´utica recibieron tambie´n un tratamiento psicoterape´utico. El tipo de terapia mostro´
ser el ma´s fuerte determinante de retencio´n al tratamiento. De las terapias utilizadas, las
orientadas a la abstinencia han mostrado la peor retencio´n. Entre los pacientes que recibieron
un tratamiento de mantenimiento con metadona, la retencio´n mejora con el aumento de
la dosis. Vivir solo, tener comorbilidad psiquia´trica y el uso de cocaı´na aumentan el
riesgo de abandono del tratamiento, mientras que recibir un tratamiento psicoterape´utico
lo disminuye.
RIASSUNTO
Il trattamento per la dipendenza da oppiacei e` efficace nel ridurre l’uso di eroina e le
conseguenze cliniche e sociali dell’uso tra i tossicodipendenti. L’efficacia del trattamento
dipende dalla sua durata. “VEdeTTE” e` uno studio di coorte italiano finanziato dal Ministero
della Salute allo scopo di valutare l’efficacia dei trattamenti offerti dai Servizi Pubblici
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per la dipendenza da sostanze (SerT). Allo studio hanno partecipato 115 SerT e 10,454
tossicodipendenti da eroina. Informazioni sulle condizioni cliniche e socio-demografiche
dei soggetti sono state raccolte all’arruolamento tramite intervista. I trattamenti ricevuti dal
soggetto sono stati registrati mediante strumenti standardizzati. Per valutare la ritenzione
in trattamento sono stati utilizzati l’analisi di sopravvivenza e il modello di Cox. Sono stati
inclusi nell’analisi 5,457 pazienti che hanno iniziato un trattamento nei 18 mesi dello studio:
tra essi, il 43.2% ha ricevuto un trattamento di mantenimento con metadone, il 10.5%
un trattamento di comunita` residenziale, ed il 46.3% una terapia orientata all’astinenza.
La probabilita` di restare in trattamento e` 0.5 dopo 179 giorni di trattamento. La dose
mediana giornaliera di metadone somministrata e` 37 mg. Il 7.6% dei pazienti che hanno
ricevuto metadone ed il 4.9% di quelli inviati in comunita` terapeutica hanno ricevuto
anche un trattamento di psicoterapia. Il tipo di terapia si e` rivelato essere il piu` forte
determinante della ritenzione in trattamento, e tra le terapie quelle orientate all’astinenza
hanno mostrato la peggiore ritenzione. Nei pazienti che hanno ricevuto trattamenti di
mantenimento con metadone, la ritenzione migliora con l’aumentare della dose. Vivere da
solo, avere comorbidita` psichiatrica e usare cocaina aumentano il rischio di abbandono del
trattamento, mentre ricevere un trattamento di psicoterapia dimezza il rischio di abbandono.
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